Vutrisiran treatment reduces GI events in ATTR-CM patients by up to 49%
PositiveFinancial Markets

Recent studies show that the treatment Vutrisiran significantly reduces gastrointestinal events in patients with ATTR-CM by up to 49%. This is a major breakthrough for those suffering from this condition, as it not only improves their quality of life but also highlights the potential of innovative therapies in managing rare diseases.
— Curated by the World Pulse Now AI Editorial System